UBE2G2 Antibody

What is UBE2G2 and what cellular functions make it important for research?

UBE2G2 (also known as UBC7) is a ubiquitin-conjugating enzyme (E2) that plays a crucial role in the ubiquitin-proteasome system, particularly in endoplasmic reticulum-associated degradation (ERAD). This 165 amino acid protein (calculated molecular weight 19 kDa, observed molecular weight 16-19 kDa) facilitates the transfer of ubiquitin moieties to target proteins, marking them for degradation .

UBE2G2 is critical for cellular homeostasis through several mechanisms:

• It forms homodimers and preassembles K48-linked polyubiquitin chains at its active site

• It partners with ER-resident E3 ligases like AMFR (gp78) to facilitate efficient removal of misfolded proteins

• It contributes to the regulation of HLA-I in immune response pathways

• It maintains ER protein quality control, preventing cellular stress from misfolded protein accumulation

The evolutionary conservation of UBE2G2 (100% sequence identity between human and mouse homologs) further underscores its biological significance, making it an important target for antibody-based research applications .

What applications are UBE2G2 antibodies validated for?

UBE2G2 antibodies have been validated for multiple research applications with specific dilution recommendations varying by manufacturer:

These antibodies have been validated in specific positive controls, including:

• Cell lines: Jurkat, HeLa, K-562, MCF7

• Tissues: Mouse testis, human prostate cancer, colon cancer, pancreatic tissue

What are the recommended protocols for UBE2G2 antibody application in Western blotting?

Western blotting for UBE2G2 requires specific considerations to ensure optimal detection of this relatively small protein (16-19 kDa). Based on validated protocols:

• Sample Preparation:

  • Use RIPA or other compatible lysis buffers with protease inhibitors

  • Include deubiquitinase inhibitors when studying UBE2G2's ubiquitin-conjugated forms

• Gel Electrophoresis:

  • Use higher percentage (12-15%) SDS-PAGE gels for better resolution of the 16-19 kDa band

  • Consider gradient gels when studying UBE2G2-ubiquitin complexes which may appear at higher molecular weights

• Transfer and Detection:

  • PVDF membranes are recommended over nitrocellulose for this lower MW protein

  • Blocking with 5% non-fat dry milk in TBST is typically sufficient

  • Primary antibody incubation: Overnight at 4°C at dilutions ranging from 1:200-1:1000

• Expected Results:

  • Detection of a clear band at 16-19 kDa representing monomeric UBE2G2

  • Potential detection of higher molecular weight bands in studies examining UBE2G2 involved in ubiquitin chain formation on its active site

Sample-dependent optimization is recommended, as indicated in the Proteintech protocol, to obtain optimal signal-to-noise ratio .

How should immunohistochemistry protocols be optimized for UBE2G2 detection?

For optimal UBE2G2 detection in tissue samples via IHC:

• Antigen Retrieval:

  • Primary method: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Dilution Optimization:

  • Initial recommended range: 1:100-1:600

  • Titration is essential for different tissue types

  • Lower dilutions (1:100) have been validated for human colon cancer and pancreatic tissue

• Detection Systems:

  • DAB-based detection systems have been validated for UBE2G2 visualization

  • Nuclear counterstaining with hematoxylin provides optimal tissue architecture context

• Validated Positive Controls:

  • Human prostate cancer tissue

  • Human colon cancer tissue

  • Human pancreatic tissue

As with all IHC applications, optimization should include antibody titration and comparison with complementary techniques like Western blotting to confirm specificity.

How can researchers implement UBE2G2 antibodies in studying protein-protein interactions with E3 ligases?

UBE2G2 functions in complex with several E3 ligases, most notably gp78. Investigating these interactions requires specialized approaches:

• Co-immunoprecipitation Studies:

  • Use UBE2G2 antibodies capable of IP (like Santa Cruz 2E6) to pull down UBE2G2 complexes

  • Analyze precipitates for associated E3 ligases (gp78/AMFR)

  • Consider domain-specific antibodies when studying interaction regions

• Proximity Ligation Assays:

  • Combine UBE2G2 antibodies with antibodies against suspected E3 ligase partners

  • Enables visualization of protein-protein interactions in situ

• G2BR Domain Considerations:

  • Be aware that the G2BR domain in proteins like AUP1 and gp78 binds with high affinity (Kᴅ ≈ 5 nM) to UBE2G2

  • This interaction may sterically hinder antibody binding to epitopes near the G2BR binding region

  • When studying G2BR-UBE2G2 interactions, epitope mapping of antibodies is essential

• UBE2G2 Dimerization:

  • UBE2G2 forms functionally important dimers through residues surrounding Cys48

  • Antibodies recognizing epitopes near this region may disrupt or be blocked from binding to dimerized UBE2G2

  • The C48A mutation creates a useful experimental system where UBE2G2 can serve as ubiquitin donor but cannot form active dimers

Experimental controls should include assessing whether the antibody disrupts E2-E3 interactions that might affect experimental outcomes.

What methodological approaches are recommended for studying UBE2G2's role in ERAD using antibodies?

Studying UBE2G2's function in ERAD requires specific methodological considerations:

• Substrate Degradation Assays:

  • Use model ERAD substrates such as TCRα-YFP

  • Monitor substrate levels by Western blot or flow cytometry

  • Apply UBE2G2 antibodies to confirm expression/knockdown in experimental systems

• UBE2G2 Active Site Analysis:

  • Study UBE2G2's active site-linked polyubiquitination using specific antibody approaches

  • Use antibodies in conjunction with UBE2G2 C48A mutant systems, which cannot accept ubiquitin to form chains at the active site

• Analysis of UBE2G2-G2BR Interactions:

  • G2BR domains from both AUP1 and gp78 are critical for UBE2G2-mediated ERAD

  • Consider using antibodies that do not interfere with G2BR binding

  • Design experiments with G2BR deletion or mutation controls

• CRISPR Knockout Validation Systems:

  • CRISPR-based UBE2G2 knockout models provide critical controls for antibody specificity

  • Example: UBE2G2 knockout in HLA-expressing cells resulted in increased HLA levels, confirming UBE2G2's role in HLA regulation

  • Rescue experiments with gRNA-resistant UBE2G2 provide additional validation

For mechanistic studies of UBE2G2 in ERAD pathways, researchers should combine antibody-based detection with functional assays and genetic manipulation.

How should researchers address potential cross-reactivity with UBE2G1 and other E2 family members?

UBE2G2 shares sequence homology with other E2 family members, particularly UBE2G1, requiring careful validation approaches:

• Specificity Validation:

  • CRISPR knockout controls have demonstrated that anti-UBE2G2 antibodies do not cross-react with UBE2G1

  • Studies have shown functionally distinct roles (e.g., UBE2G1 knockout did not affect HLA expression while UBE2G2 knockout did)

• Recommended Controls:

  • Include samples with UBE2G1 overexpression to verify antibody specificity

  • Use CRISPR knockouts of both UBE2G1 and UBE2G2 when available

  • Consider dual immunoblotting with antibodies against both proteins

• Application-Specific Considerations:

  • For IHC applications, validate with UBE2G2-null tissues when possible

  • For IP applications, confirm pulled-down protein identity with mass spectrometry

  • For functional studies, include UBE2G1 as a negative control in experimental design

The search results indicate that while UBE2G1 and UBE2G2 are homologs, they have distinct functions, with CRISPR experiments confirming that targeting UBE2G1 did not affect eGFP-HLA-A2 expression while UBE2G2 knockout significantly rescued expression .

How can UBE2G2 antibodies be utilized to investigate the structural basis of UBE2G2 dimerization and function?

UBE2G2 dimerization is critical for its function in assembling ubiquitin chains. Investigating this process requires specialized approaches:

• Epitope Mapping Considerations:

  • Key residues for UBE2G2 dimerization are located around Cys48

  • Antibodies targeting this region may interfere with dimerization

  • Structure-based modeling can help predict which antibody epitopes might affect dimerization

• Mutant Analysis Systems:

  • The C48A mutation creates a valuable experimental system:

    • UBE2G2 C48A can serve as ubiquitin donor

    • Cannot accept ubiquitin to form chains at active site

    • Fails to promote degradation of ERAD substrates in cells

  • Antibodies can be used to track wild-type vs. mutant UBE2G2 in comparative studies

• Crosslinking Experiments:

  • In vivo and in vitro crosslinking has confirmed UBE2G2 dimerization

  • Wild-type UBE2G2 forms significantly more oligomers than the C48A mutant

  • Antibodies can be used to detect these crosslinked species

• Interaction with G2BR Domains:

  • The structure of UBE2G2 in complex with G2BR peptides has been determined

  • Key contact residues include Leu-163, Leu-165, Met-42, and Phe-51

  • Antibodies targeting these regions may interfere with G2BR binding

A combined approach using structural information, antibody epitope mapping, and functional assays provides the most comprehensive analysis of UBE2G2 structure-function relationships.

What methodological approaches should researchers consider when studying UBE2G2's interaction with specific substrates?

Investigating UBE2G2's role in ubiquitinating specific substrates requires specialized methodological considerations:

• Substrate-Specific Ubiquitination Assays:

  • Established models include:

    • TCRα-YFP for ERAD studies

    • HLA-I for immune regulation pathways

    • 3-hydroxy-3-methylglutaryl coenzyme A reductase for sterol-regulated degradation

  • Antibodies can confirm UBE2G2 expression/knockdown in these systems

• In Vitro Reconstitution Systems:

  • Single-round ubiquitin turnover assays using:

    • Ube2g2 precharged with Flag-UbK48R (donor)

    • Ube2g2 precharged with untagged wild-type ubiquitin (acceptor)

  • Use antibodies to detect ubiquitinated species or to immunodeplete components

• Structural Considerations:

  • UBE2G2's interaction with gp78 occurs within a large heterooligomeric complex

  • This brings multiple UBE2G2 molecules into proximity for polyubiquitination

  • Antibodies targeting dimerization interfaces may disrupt this process

• E3 Ligase Dependency Analysis:

  • Different UBE2G2-dependent substrates require different E3 ligases:

    • gp78 for some ERAD substrates

    • HRD1 for others

    • AUP1 for facilitation

  • Experimental design should account for these specific E2-E3 pairs

Combining biochemical approaches with structural information and antibody-based detection provides comprehensive insight into UBE2G2's substrate-specific functions.

What are the most common technical challenges when using UBE2G2 antibodies and how can they be addressed?

Several technical challenges may arise when working with UBE2G2 antibodies:

• Low Signal Intensity:

  • Potential causes: Low UBE2G2 expression, insufficient antibody concentration, degraded antibody

  • Solutions:

    • Increase antibody concentration within recommended range (e.g., 1:200 instead of 1:1000 for WB)

    • Use positive control samples (Jurkat cells, HeLa cells, K-562 cells, mouse testis tissue)

    • Ensure proper storage conditions (typically -20°C with glycerol, avoid repeated freeze-thaw cycles)

• Multiple Bands in Western Blot:

  • Potential causes: UBE2G2 dimerization, ubiquitin conjugation, isoforms, non-specific binding

  • Solutions:

    • Include reducing agents in sample buffer

    • Verify with UBE2G2 knockout/knockdown controls

    • For C48A mutant systems, expect altered band patterns due to inability to form active site-linked chains

• Inconsistent IHC Staining:

  • Potential causes: Variable antigen accessibility, fixation issues

  • Solutions:

    • Try alternative antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

    • Test different dilutions (1:100-1:600 range)

    • Compare with matching WB on same tissue samples

• Epitope Masking in Protein Interaction Studies:

  • Potential cause: G2BR domains from interaction partners may block antibody access

  • Solution: Select antibodies with epitopes away from known interaction surfaces

Regular validation with appropriate controls and optimization for specific applications are essential for reliable UBE2G2 antibody performance.

How can researchers validate the specificity of UBE2G2 antibodies in experimental systems?

Rigorous validation of UBE2G2 antibody specificity is critical for reliable research outcomes:

• Genetic Validation Approaches:

  • CRISPR/Cas9 knockout of UBE2G2 provides the gold standard for antibody validation

  • siRNA knockdown offers an alternative when CRISPR is not feasible

  • Rescue experiments with gRNA-resistant UBE2G2 constructs provide additional validation

• Comparative Analysis:

  • Test multiple antibodies targeting different epitopes

  • Compare performance across applications (WB, IHC, IF)

  • Verify consistency between different detection methods

• Functional Validation:

  • Correlate antibody detection with functional outcomes (e.g., ERAD substrate accumulation)

  • Use the C48A mutant system to confirm specific recognition of functional vs. non-functional UBE2G2

• Cross-Reactivity Assessment:

  • Test in systems with UBE2G1 overexpression (closest homolog)

  • Verify lack of signal in UBE2G2 knockout systems

  • CRISPR experiments have confirmed that UBE2G1 and UBE2G2 have distinct functions

Implementing these validation approaches ensures that experimental results accurately reflect UBE2G2 biology rather than antibody artifacts.